Vista Pharmaceuticals share news and announcements
BSE: 524711Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹5.48.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹36 Cr3,508th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −28.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −32.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.27
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,933
Vista Pharmaceuticals share news and announcements
532 announcements, routine notices left out, newest first. Page 6 of 11.
Jun 2020
25 Jun · Board meeting
May 2020
15 May · Board meeting
Meeting on 25 May 2020: preferential issue of shares14 May · Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015-Reg
13 May · Shareholding for the Period Ended March 31, 2020
Shareholding Pattern for the Period Ended March 31, 2020. For more details, kindly Click ....13 May · Certificate In Terms Of Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Apr 2020
21 Apr · Statement Of Investor Complaints For The Quarter Ended March 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Feb 2020
13 Feb · Results
4 Feb · Board meeting
Meeting on 13 Feb 2020: quarterly results
Jan 2020
16 Jan · Shareholding for the Period Ended December 31, 2019
Shareholding Pattern for the Period Ended December 31, 2019. For more details, kindly Click ....13 Jan · Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Nov 2019
6 Nov · Legal
Exchange has sought clarification Vista Pharmaceuticals Ltd on 06th November, 2019 with reference to significant movement in price, in order to ensure that investors have latest relevant ....
Oct 2019
29 Oct · Board meeting
Meeting on 7 Nov 2019: quarterly results25 Oct · Certificate In Terms Of Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
15 Oct · Shareholding for the Period Ended September 30, 2019
Shareholding Pattern for the Period Ended September 30, 2019. For more details, kindly Click ....15 Oct · Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 For The Half Year Ended 30.09.2019
15 Oct · Statement Of Investor Complaints For The Quarter Ended September 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Sep 2019
30 Sep · Board meeting
19 Sep · Results
Details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly ....
Aug 2019
7 Aug · Board meeting
Meeting on 14 Aug 2019: annual general meeting and quarterly results
Jul 2019
19 Jul · Shareholding for the Period Ended June 30, 2019
Shareholding Pattern for the Period Ended June 30, 2019. For more details, kindly Click ....19 Jul · Statement Of Investor Complaints For The Quarter Ended June 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 0 0 0
Jun 2019
10 Jun · Update On Conversion Of Warrants Into Equity Shares
May 2019
30 May · Update On Conversion Of Warrants Into Equity Shares
22 May · Board meeting
Meeting on 30 May 2019: audited results
Apr 2019
27 Apr · Certificate In Terms Of Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
18 Apr · Submission Of Compliance Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015- For The Half Year Ended 31St March, 2019.
16 Apr · Shareholding for the Period Ended March 31, 2019
Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click ....15 Apr · Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0 3 3 0
Mar 2019